As threat of drug-resistance grows, Big Pharma decreases investments in TB research by 22 percent.

The Stop TB Partnership has prepared a roadmap of meetings, workshops and other events organized by partners during and before the World Conference on Lung Health in Paris.

The guidelines describe FDA-approved and off-label uses of bedaquiline in populations with multidrug-resistant tuberculosis that were not included in clinical trials. 

Médecins Sans Frontières would like to treat 300 drug resistant TB patients in Khayelitsha with linezolid, but can only afford to buy the drug for little more than 20 patients.

A report designed to support the voices of those who often find themselves forgotten among the numbers.

Gains in tuberculosis control at risk due to 3 million missed patients and drug resistance.

An analysis of patent, competition and medicines law.

Health activists hand-over comments on Draft National Policy on Intellectual Property to Department of Trade and Industry, supporting patent law reform.

The new paradigm in TB treatment focuses on using existing drugs and evaluating them in combination to develop better, shorter regimens.

An open letter from civil society, academics and experts supports a number of proposed reforms in the Draft National Policy on Intellectual Property, and offers specific recommendations for further improvements.